Table 5 Prognostic factors for time to next treatment
Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
Covariate | P | HR (95% CI) | P | HR (95% CI) |
Sex (ref: Male) | 0.0014 | 0.835 (0.747–0.933) | 0.0013 | 0.825 (0.733–0.928) |
Age (ref: < 75 years old) | 0.0023 | 1.374 (1.120–1.686) | – | – |
Histotype (ref: Other) | ||||
LMS | 0.5114 | 0.955 (0.831–1.097) | – | – |
DLPS | 0.0068 | 1.357 (1.088–1.692) | – | – |
MPNST | 0.3703 | 1.154 (0.843–1.580) | – | – |
SS | 0.8580 | 0.983 (0.811–1.191) | – | – |
UPS | 0.0375 | 1.243 (1.013–1.525) | – | – |
Grade (ref: < 3) | < 0.0001 | 1.417 (1.258–1.596) | < 0.0001 | 1.372 (1.218–1.546) |
Number of metastatic sites (ref: 1) | 0.1175 | 1.118 (0.972–1.285) | – | – |
Liver metastasis (ref: no) | 0.1436 | 1.103 (0.967–1.259) | – | – |
Locoregional treatment (ref: no) | < 0.0001 | 0.496 (0.442–0.556) | < 0.0001 | 0.487 (0.432–0.550) |
Clinical trial in first line (ref: no) | 0.6453 | 1.048 (0.859–1.277) | – | – |
Anthracycline in first line (ref: no) | < 0.0001 | 0.756 (0.674–0.847) | – | – |
Polychemotherapy in first line (ref: no) | < 0.0001 | 0.729 (0.651–0.815) | < 0.0001 | 0.743 (0.660–0.836) |